Stable Istotope Labelled Rovalpituzumab Biosimilar – Anti-DLL3 mAb – Research Grade

Reference: PX-TA1397-SIL-1MG
Size

Brand

Product type

Clonality

Expression system

Applications

Product nameStable Istotope Labelled Rovalpituzumab Biosimilar - Anti-DLL3 mAb - Research Grade
SourceCAS 1613313-01-1
SpeciesHumanized
Expression systemMammalian cells
Purity>95%
BufferPBS buffer PH7.5
Delivery conditionBlue Ice
Delivery Time3-5 days if in stock; 5-8 weeks if production needed
Storage conditionstore at -80°C
BrandProteoGenix
ReferencePX-TA1397-SIL
NoteFor research use only. Not suitable for clinical or therapeutic use.
IsotypeIgG1-kappa
ClonalityMonoclonal Antibody
FormatLyophilized
LabellingArginine: 13C6,15N4 ; Lysine: 13C6,15N2, >99%
Isotopic Enrichment99%
Stability1 year

General information on Anti-DLL3[Homo sapiens] (Rovalpituzumab) Monoclonal Antibody

Rovalpituzumab has been investigated for the treatment of Glioblastoma, Malignant Melanoma, Other Solid Tumors, Small Cell Lung Cancer, and Medullary Thyroid Cancer.

Reviews

There are no reviews yet.

REVIEW YOUR PRODUCT

Be the first to review “Stable Istotope Labelled Rovalpituzumab Biosimilar – Anti-DLL3 mAb – Research Grade”

Your email address will not be published. Required fields are marked *

Contact us

Send us a message from the form below